SCTL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCTL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Societal CDMO has the Growth Rank of 5.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Growth Rank distribution charts can be found below:
* The bar in red indicates where Societal CDMO's Growth Rank falls into.
Thank you for viewing the detailed overview of Societal CDMO's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Bryan M. Reasons | director | C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544 |
Elena Cant | director | C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341 |
Enloe J David Jr | director, officer: Chief Executive Officer | |
James Charles Miller | director | 490 LAPP ROAD, MALVERN PA 19355 |
Wayne Weisman | director | 490 LAPP ROAD, MALVERN PA 19355 |
William Ashton | director | C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073 |
Winston J Churchill | director | C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087 |
Awm Investment Company, Inc. | 10 percent owner | 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Mathew Paul Arens | director, 10 percent owner | C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435 |
First Light Asset Management, Llc | director, 10 percent owner | 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435 |
Laura L. Parks | director | C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355 |
Michael Berelowitz | director | 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016 |
Ryan David Lake | officer: Chief Financial Officer | KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341 |
Scp Vitalife Partners (israel) Ii, L.p. | 10 percent owner | SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
Scp Vitalife Partners Ii Lp | 10 percent owner | SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
From GuruFocus
By sperokesalga sperokesalga • 05-09-2023
By Marketwired • 07-10-2023
By sperokesalga sperokesalga • 04-12-2023
By Marketwired • 06-29-2023
By Marketwired • 08-09-2023
By Marketwired • 08-24-2023
By Marketwired • 09-20-2023
By sperokesalga sperokesalga • 03-20-2023
By Marketwired • 09-25-2023
By Marketwired • 08-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.